| 1. |
- Glasbey, JC, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Ravaioli, A, et al.
(författare)
-
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.
- 2008
-
Ingår i: Annals of oncology. - : Elsevier BV. - 1569-8041 .- 0923-7534. ; 19:4, s. 660-668
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Low p27 and high Skp2 immunoreactivity are associated with a poor prognosis and other poor prognostic features including resistant phenotypes and antiestrogen drug resistance. We investigated these proteins in two International Breast Cancer Study Group trials studying node-negative early breast cancer. PATIENTS AND METHODS: Trial VIII compared chemotherapy followed by goserelin with either modality alone in premenopausal patients. Trial IX compared chemotherapy followed by tamoxifen with tamoxifen alone in postmenopausal patients. Central Pathology Office assessed p27 and Skp2 expression in the primary tumor by immunohistochemistry among 1631 (60%) trial patients. RESULTS: p27 and Skp2 were inversely related; 13% of tumors expressed low p27 and high Skp2. Low p27 and high Skp2 were associated with unfavorable prognostic factors including larger size and higher grade tumors, absence of estrogen receptor and progesterone receptor, human epidermal growth factor receptor 2 overexpression and high Ki-67 (each P < 0.05). Low p27 and high Skp2 were not associated with disease-free survival (P = 0.42 and P = 0.48, respectively). The relative effects of chemo-endocrine versus endocrine therapy were similar regardless of p27 or Skp2. CONCLUSIONS: We confirm the association of low p27 and high Skp2 with other poor prognostic features, but found no predictive or prognostic value, and therefore do not recommend routine determination of p27 and Skp2 for node-negative breast cancer.
|
|
| 5. |
|
|
| 6. |
- Lindström, Björn, et al.
(författare)
-
Fast failures in the LHC and the future high luminosity LHC
- 2020
-
Ingår i: Physical Review Accelerators and Beams. - : AMER PHYSICAL SOC. - 2469-9888. ; 23:8
-
Tidskriftsartikel (refereegranskat)abstract
- An energy of 362 MJ is stored in each of the two LHC proton beams for nominal beam parameters. This will be further increased to about 700 MJ in the future high luminosity LHC (HL-LHC) and uncontrolled beam losses represent a significant hazard for the integrity and safe operation of the machine. In this paper, a number of failure mechanisms that can lead to a fast increase of beam losses are analyzed. Most critical are failures in the magnet protection system, namely the quench heaters and a novel protection system called coupling-loss induced quench (CLIQ). An important outcome is that magnet protection has to be evaluated for its impact on the beam and designed accordingly. In particular, CLIQ, which is to protect the new HL-LHC triplet magnets, constitutes the fastest known failure in the LHC if triggered spuriously. A schematic change of CLIQ to mitigate the hazard is presented. A loss of the beam-beam kick due to the extraction of one beam is another source of beam losses with a fast onset. A significantly stronger impact is expected in the upcoming LHC Run III and HL-LHC as compared to the current LHC, mainly due to the increased bunch intensity. Its criticality and mitigation methods are discussed. It is shown that symmetric quenches in the superconducting magnets for the final focusing triplet can have a significant impact on the beam on short timescales. The impact on the beam due to failures of the beam-beam compensating wires as well as coherent excitations by the transverse beam damper are also discussed.
|
|
| 7. |
- Ravaioli, F, et al.
(författare)
-
DNA Methylation Analysis of Ribosomal DNA in Adults With Down Syndrome
- 2022
-
Ingår i: Frontiers in genetics. - : Frontiers Media SA. - 1664-8021. ; 13, s. 792165-
-
Tidskriftsartikel (refereegranskat)abstract
- Control of ribosome biogenesis is a critical aspect of the regulation of cell metabolism. As ribosomal genes (rDNA) are organized in repeated clusters on chromosomes 13, 14, 15, 21, and 22, trisomy of chromosome 21 confers an excess of rDNA copies to persons with Down syndrome (DS). Previous studies showed an alteration of ribosome biogenesis in children with DS, but the epigenetic regulation of rDNA genes has not been investigated in adults with DS so far. In this study, we used a targeted deep-sequencing approach to measure DNA methylation (DNAm) of rDNA units in whole blood from 69 adults with DS and 95 euploid controls. We further evaluated the expression of the precursor of ribosomal RNAs (RNA45S) in peripheral blood mononuclear cells (PBMCs) from the same subjects. We found that the rDNA promoter tends to be hypermethylated in DS concerning the control group. The analysis of epihaplotypes (the combination of methylated and unmethylated CpG sites along the same DNA molecule) showed a significantly lower intra-individual diversity in the DS group, which at the same time was characterized by a higher interindividual variability. Finally, we showed that RNA45S expression is lower in adults with DS. Collectively, our results suggest a rearrangement of the epigenetic profile of rDNA in DS, possibly to compensate for the extranumerary rDNA copies. Future studies should assess whether the regulation of ribosome biogenesis can contribute to the pathogenesis of DS and explain the clinical heterogeneity characteristic of the syndrome.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Gensous, N, et al.
(författare)
-
A Targeted Epigenetic Clock for the Prediction of Biological Age
- 2022
-
Ingår i: Cells. - : MDPI AG. - 2073-4409. ; 11:24
-
Tidskriftsartikel (refereegranskat)abstract
- Epigenetic clocks were initially developed to track chronological age, but accumulating evidence indicates that they can also predict biological age. They are usually based on the analysis of DNA methylation by genome-wide methods, but targeted approaches, based on the assessment of a small number of CpG sites, are advisable in several settings. In this study, we developed a targeted epigenetic clock purposely optimized for the measurement of biological age. The clock includes six genomic regions mapping in ELOVL2, NHLRC1, AIM2, EDARADD, SIRT7 and TFAP2E genes, selected from a re-analysis of existing microarray data, whose DNA methylation is measured by EpiTYPER assay. In healthy subjects (n = 278), epigenetic age calculated using the targeted clock was highly correlated with chronological age (Spearman correlation = 0.89). Most importantly, and in agreement with previous results from genome-wide clocks, epigenetic age was significantly higher and lower than expected in models of increased (persons with Down syndrome, n = 62) and decreased (centenarians, n = 106; centenarians’ offspring, n = 143; nutritional intervention in elderly, n = 233) biological age, respectively. These results support the potential of our targeted epigenetic clock as a new marker of biological age and open its evaluation in large cohorts to further promote the assessment of biological age in healthcare practice.
|
|
